Trial Profile
Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccines
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs GSK 2321138A (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 28 Dec 2019 Results assessing safety events occurring after vaccination published in the Drug Safety
- 10 Feb 2019 Status changed from recruiting to completed.
- 07 Jan 2019 Status changed from not yet recruiting to recruiting.